New drug cocktail targets Hard-to-Treat lung cancer

NCT ID NCT03202940

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether combining two targeted drugs, alectinib and cobimetinib, can safely treat advanced ALK-positive non-small cell lung cancer. Researchers will first find the best dose with acceptable side effects, then measure how often tumors shrink. The trial enrolls 16 adults whose cancer has spread and carries the ALK gene change.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alectinib and cobimetinib
What this could lead to: If this combination works, it could offer a new treatment option for people with ALK-positive lung cancer whose disease has stopped responding to standard therapy.
What could go wrong: This is an early-phase trial with only 16 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Massachusetts general Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.